MimiVax, LLC
MimiVax is a biopharmaceutical company dedicated to disrupting cancer through the development of highly innovative immunotherapies aimed at increasing patient survival rates. Their lead product, SurVaxM, targets survivin, a protein expressed in many cancers, including glioblastoma, and aims to stimulate the immune system to recognize and attack cancer cells. The company is involved in clinical trials for SurVaxM in various cancers and has received FDA designations to support its development. MimiVax was formed in 2012 from Roswell Park Comprehensive Cancer Center and is committed to improving outcomes for cancer patients while strengthening the biomedical startup ecosystem in Buffalo, New York.
Industries
Nr. of Employees
small (1-50)
MimiVax, LLC
Products
SurVaxM
A peptide-mimic immunotherapeutic vaccine designed to target survivin, intended to stimulate antigen-specific T‑cell and antibody responses to control tumor growth and reduce recurrence; delivered by subcutaneous injection in an adjuvanted formulation.
SurVaxM
A peptide-mimic immunotherapeutic vaccine designed to target survivin, intended to stimulate antigen-specific T‑cell and antibody responses to control tumor growth and reduce recurrence; delivered by subcutaneous injection in an adjuvanted formulation.
Services
Sponsorship and operational leadership of oncology clinical trials from Phase I through randomized Phase 2b studies, including protocol development, site selection and trial oversight.
Structuring and executing licensing agreements and strategic partnerships to enable regional clinical development and commercialization.
Coordination with contract development and manufacturing organizations for formulation development, sterile drug-product manufacture and scale-up of clinical batches.
Sponsorship and operational leadership of oncology clinical trials from Phase I through randomized Phase 2b studies, including protocol development, site selection and trial oversight.
Structuring and executing licensing agreements and strategic partnerships to enable regional clinical development and commercialization.
Coordination with contract development and manufacturing organizations for formulation development, sterile drug-product manufacture and scale-up of clinical batches.
Expertise Areas
- Clinical trial management
- Immuno-oncology vaccine development
- Translational and preclinical research
- Immune monitoring and biomarker development
Key Technologies
- Peptide-mimic vaccine design
- Adjuvanted subcutaneous vaccine formulations
- T-cell assays and antibody (IgG) titration
- Flow cytometry and immune cell phenotyping
News & Updates
MimiVax announced that its fully enrolled Phase 2b clinical trial of SurVaxM in glioblastoma has successfully progressed following an interim analysis of trial data, supporting continued advancement of the trial.
The FDA has granted Fast Track Designation to SurVaxM for the treatment of newly diagnosed glioblastoma, facilitating faster development and review processes.
The Phase 2A study of SurVaxM in newly diagnosed glioblastoma showed promising results with increased survival rates, published in the Journal of Clinical Oncology.
The study found that 51% of patients survived at least 2 years and 41% survived 3 years, higher than historical data.
MimiVax announced that its fully enrolled Phase 2b clinical trial of SurVaxM in glioblastoma has successfully progressed following an interim analysis of trial data, supporting continued advancement of the trial.
The FDA has granted Fast Track Designation to SurVaxM for the treatment of newly diagnosed glioblastoma, facilitating faster development and review processes.
The Phase 2A study of SurVaxM in newly diagnosed glioblastoma showed promising results with increased survival rates, published in the Journal of Clinical Oncology.
The study found that 51% of patients survived at least 2 years and 41% survived 3 years, higher than historical data.